Gene shot into heart shows promise in early safety trial

NCT ID NCT01422772

Completed Disease control Sponsor: Helixmith Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a gene therapy called VM202RY in 9 people with ischemic heart disease who had incomplete revascularization after bypass surgery. The therapy was injected directly into heart muscle areas that still had poor blood flow. The main goal was to check safety over 6 months, and researchers also looked at changes in heart function using MRI.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VM202RY (Engensis) gene therapy
What this could lead to: If successful, this could lead to a new gene-based treatment to improve blood flow and heart function in people with severe heart disease who cannot be fully treated with bypass surgery alone.
What could go wrong: This is a very early, small trial with only 9 participants, so results may not apply to everyone. The main goal is safety, not effectiveness, and gene therapies can have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC HEART DISEASE

Contacts and locations

Locations

Seoul National University Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.